miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation

Zhang,Dingwei; Li,Zhangjun; Zhang,Yanfei; Tu,Chen; Huo,Jia; Liu,Yan

doi:10.3892/or.2016.5190

miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation

Authors:
- Dingwei Zhang
- Zhangjun Li
- Yanfei Zhang
- Chen Tu
- Jia Huo
- Yan Liu
View Affiliations

Affiliations: Department of Dermatology, The Second Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: October 21, 2016 https://doi.org/10.3892/or.2016.5190
Pages: 3657-3663

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alterations in the levels and functions of microRNAs (miRs) have been associated with carcinogenesis. In this study, we investigated the role and underlying mechanism of miR-4262 in the proliferation of human cutaneous malignant melanoma (CMM) cells. The expression levels of miR-4262 were significantly upregulated in cancerous tissues compared with those in matched adjacent normal tissues from 110 CMM patients. miR-4262 was also regulated in five types of CMM cell lines, displaying an opposite expression pattern to that of Kruppel-like 6 (KLF6), a proven tumor suppressor in several cancers other than CMM. KLF6 overexpression sharply reduced A375 cell proliferation, suppressed the activation of epidermal growth factor receptor (EGFR) and increased p21 expression levels, while knockdown of KLF6 by siRNA transfection had an opposite effect. Furthermore, KLF6 was proven to be a direct target gene of miR-4262 by bioinformatic analysis and KLF6‑3'UTR luciferase reporter assay. Finally, our data on miR-4262 mimic and inhibitor transfection indicated that miR-4262 could markedly reduce the expression of KLF6 protein and had a stimulatory effect on A375 cell proliferation. Our findings indicate that KLF6 acts as a tumor suppressor in CMM cells and miR-4262 promotes the proliferation of CMM cells through KLF6-mediated EGFR inactivation and p21 upregulation.

View Figures

View References

1	Moan JE, Baturaite Z, Dahlback A and Porojnicu AC: Ultraviolet radiation and cutaneous malignant melanoma. Adv Exp Med Biol. 810:359–374. 2014.PubMed/NCBI
2	Law MH, Bishop DT, Lee JE, Brossard M, Martin NG, Moses EK, Song F, Barrett JH, Kumar R, Easton DF, et al: GenoMEL Consortium; Essen-Heidelberg Investigators; SDH Study Group; Q-MEGA and QTWIN Investigators; AMFS Investigators; ATHENS Melanoma Study Group: Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet. 47:987–995. 2015. View Article : Google Scholar : PubMed/NCBI
3	Emri G, Emri E, Boros G, Hegedűs C, Janka E, Gellén E and Remenyik E: Skin carcinogenesis: the pathogenetic and therapeutic role of zinc. J Metallomics Nanotechnol. 2:19–26. 2015.
4	Atkins GB and Jain MK: Role of Krüppel-like transcription factors in endothelial biology. Circ Res. 100:1686–1695. 2007. View Article : Google Scholar : PubMed/NCBI
5	DiFeo A, Martignetti JA and Narla G: The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat. 12:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
6	Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, et al: Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65:5761–5768. 2005. View Article : Google Scholar : PubMed/NCBI
7	Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S and Tal-Kremer S: Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 126:1090–1103. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, et al: Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology. 40:1047–1052. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ebrahimi A, Nodushan SMHT, Mousavian A, Mokarizadeh A, Abbasi M, Yahaghi E and Rasaei SM: Diagnostic and prognostic potentials of KLF6 and HER3 expression alterations in cutaneous malignant melanoma. Tumour Biol. Oct 16–2015.(Epub ahead of print). View Article : Google Scholar
10	Cai D, Zhao J and Sun Q: Kruppel-like factor 6 in the progression and prognosis of malignant melanoma. J Int Med Res. 42:184–190. 2014. View Article : Google Scholar : PubMed/NCBI
11	Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, et al: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68:664–673. 2008. View Article : Google Scholar : PubMed/NCBI
12	Goff LA, Davila J, Swerdel MR, Moore JC, Cohen RI, Wu H, Sun YE and Hart RP: Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One. 4:e71922009. View Article : Google Scholar : PubMed/NCBI
13	Rönnau CG, Verhaegh GW, Luna-Velez MV and Schalken JA: Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int. 2014:5917032014. View Article : Google Scholar : PubMed/NCBI
14	Pouliot LM, Shen D-W, Suzuki T, Hall MD and Gottesman MM: Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Exp Cell Res. 319:566–574. 2013. View Article : Google Scholar : PubMed/NCBI
15	Jing L, Jin C, Lu Y, Huo P, Zhou L, Wang Y and Tian Y: Investigation of microRNA expression profiles associated with human alcoholic cardiomyopathy. Cardiology. 130:223–233. 2015. View Article : Google Scholar : PubMed/NCBI
16	Gao S, Wang J, Xie J, Zhang T and Dong P: Role of miR-138 in the regulation of larynx carcinoma cell metastases. Tumour Biol. Oct 24–2015.(Epub ahead of print).
17	Song K, Liu N, Yang Y and Qiu X: Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262. Tumour Biol. 37:6493–6499. 2015. View Article : Google Scholar : PubMed/NCBI
18	Bao H, Gao F, Xie G and Liu Z: Angiotensin-converting enzyme 2 inhibits apoptosis of pulmonary endothelial cells during acute lung injury through suppressing miR-4262. Cell Physiol Biochem. 37:759–767. 2015. View Article : Google Scholar : PubMed/NCBI
19	Huang X, Le Q-T and Giaccia AJ: MiR-210 - micromanager of the hypoxia pathway. Trends Mol Med. 16:230–237. 2010. View Article : Google Scholar : PubMed/NCBI
20	Chan YC, Banerjee J, Choi SY and Sen CK: miR-210: The master hypoxamir. Microcirculation. 19:215–223. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang H, Flach H, Onizawa M, Wei L, McManus MT and Weiss A: Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol. 15:393–401. 2014. View Article : Google Scholar : PubMed/NCBI
22	Qin Q, Furong W and Baosheng L: Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res. 33:502014. View Article : Google Scholar : PubMed/NCBI
23	Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, et al: KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med. 5:169ra12. 2013. View Article : Google Scholar : PubMed/NCBI
24	Zhenzhen Z, De'an T, Limin X, Wei Y and Min L: New candidate tumor-suppressor gene KLF6 and its splice variant KLF6 SV2 counterbalancing expression in primary hepatocarcinoma. Hepatogastroenterology. 59:473–476. 2012. View Article : Google Scholar : PubMed/NCBI
25	Andreoli V, Gehrau RC and Bocco JL: Biology of Krüppel-like factor 6 transcriptional regulator in cell life and death. IUBMB Life. 62:896–905. 2010. View Article : Google Scholar : PubMed/NCBI
26	Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, Kulp SK, Teng CM, Wang Q and Chen CS: Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J Biol Chem. 286:9968–9976. 2011. View Article : Google Scholar : PubMed/NCBI
27	Lang UE, Kocabayoglu P, Cheng GZ, Ghiassi-Nejad Z, Muñoz U, Vetter D, Eckstein DA, Hannivoort RA, Walsh MJ and Friedman SL: GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene. 32:4557–4564. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, et al: Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest. 122:2637–2651. 2012. View Article : Google Scholar : PubMed/NCBI